Method for Prognosing the Course of a Sars-Cov-2 Infection and the Response to a Sars-Cov-2 Immunization And/or Natural Infection by Measuring Soluble Ace2

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention discloses an in-vitro method and related assay kits for predicting both the likely severity of a SARS-CoV-2 (COVID-19) infection and how effectively an individual will respond to a COVID-19 vaccine or natural SARS-CoV-2 infection. The method works by measuring specific forms of soluble ACE2 (sACE2 and a-sACE2) in a patient's biological sample (e.g. blood serum or plasma). Elevated levels of these markers are correlated with an increased risk of severe COVID-19 and a lower likelihood of mounting an effective immune response to vaccination or infection. The invention includes sensitive and accurate test kits for laboratory use to determine these marker levels and classify patient risk.

Use CasesContent extracted from patent full text and abstract with AI.

• Screening patients before COVID-19 vaccination to identify those unlikely to respond effectively, allowing optimized use of vaccine resources or alternative immunization strategies.
• Monitoring SARS-CoV-2 infected individuals to predict the risk of severe disease, helping guide early clinical intervention, hospital resource allocation, and patient prioritization.
• Identifying at-risk individuals in the general population or specific sub-populations (e.g. elderly or co-morbid patients) for targeted public health measures.
• Supporting research into the mechanisms underlying immune response failure or severe COVID-19 outcomes by providing a reliable biomarker assay.
• Stratifying participants in vaccine or therapeutic clinical trials based on pre-existing sACE2/a-sACE2 levels.
• Potential use in screening for susceptibility to reinfection or breakthrough infections in vaccinated individuals.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables early and individualized risk assessment for severe COVID-19 or vaccine non-response using an objective biomarker.
• Facilitates better clinical and public health decision-making, including patient triage and more effective vaccine allocation.
• Test kits are designed for high accuracy and sensitivity, outperforming conventional ELISA in detecting critical ACE2 marker levels.
• May help avoid unnecessary vaccination or inappropriate reassurance by identifying poor responders who remain vulnerable post-vaccination.
• Improves hospital preparedness by forecasting which patients are at elevated risk for needing intensive medical care.
• Can contribute to enhanced research and data collection regarding host-pathogen interactions and immunization efficacy.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to an in-vitro-method for prognosing the course of a SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection and/or the response to a SARS-CoV-2 immunization and/or SARS-CoV-2 natural infection of a subject by using a-sACE2 and/or sACE2 as a marker. The invention further discloses an in-vitro-assay (A) for determining the amount of a-sACE2 and to an in-vitro-assay (B) for determining the amount of sACE2 in a sample. Additionally, a kit of parts for performing the in-vitro-assay (A), a kit of parts for performing the in-vitro-assay (B) and a kit of parts (C) for performing the in-vitro-method of the present invention are disclosed. Moreover, the present invention relates to a-sACE2 and/or sACE2 as a marker for prognosing the course of a SARS-CoV-2-infection and/or the response to a SARS-CoV-2 immunization and/or SARS-CoV-2 natural infection.